People taking Mounjaro in clinical trials lost between 15% and 21% of their body weight over 72 weeks, depending on the dose. For someone starting at 250 pounds, that translates to roughly 37 to 52 pounds. These are averages, and individual results vary, but Mounjaro consistently produces more weight loss than any other injectable medication currently available.
Weight Loss by Dose
Mounjaro (tirzepatide) comes in several doses, and the amount of weight you lose scales with how high you go. In the landmark SURMOUNT-1 trial, which followed participants for 72 weeks, average body weight loss broke down like this:
- 5 mg: 15% of body weight
- 10 mg: 19.5% of body weight
- 15 mg: 20.9% of body weight
The placebo group, by comparison, lost about 3.1%. Everyone in the trial also received lifestyle counseling, so these numbers reflect the drug’s effect on top of basic diet and activity guidance.
In studies focused on people with type 2 diabetes, where weight loss tends to be more modest, the range was still meaningful. Across the SURPASS trials, participants on the 5 mg dose lost 12 to 17 pounds over 40 to 52 weeks, while those on the 15 mg dose lost 19 to 25 pounds. Diabetes medications that affect blood sugar can sometimes blunt weight loss, so these numbers are generally lower than what people without diabetes experience.
What the First Few Months Look Like
Everyone starts at 2.5 mg, which is a dose designed for your body to adjust rather than to produce dramatic results. During the first month, most people lose 2 to 4 pounds as appetite suppression gradually kicks in and portion sizes shrink without much effort. The dose increases every four weeks during the titration phase.
By months two and three, when you move to 5 mg, weight loss typically accelerates to 1 to 2 pounds per week. Many people see a 5% to 8% total body weight reduction in this window. The steepest period of loss usually happens between months three and nine as the dose continues to climb. Weight loss doesn’t stop abruptly after that, but it does slow and eventually plateaus, usually somewhere between 12 and 18 months.
How It Compares to Semaglutide
Mounjaro outperforms semaglutide (the active ingredient in Ozempic and Wegovy) in every head-to-head comparison published so far. In the SURMOUNT-5 study, which directly pitted tirzepatide against semaglutide in adults without diabetes, tirzepatide produced 47% greater weight loss overall. The numbers: 20.2% body weight lost with tirzepatide versus 13.7% with semaglutide. In absolute terms, that was 50.3 pounds versus 33.1 pounds.
Waist circumference followed the same pattern. People on tirzepatide lost 7.2 inches from their waist compared to 5.1 inches with semaglutide. The difference comes down to how the drug works. Semaglutide activates one gut hormone pathway (GLP-1), while tirzepatide activates two: GLP-1 and GIP. That dual action appears to improve how the body regulates energy balance and fat storage beyond what GLP-1 alone can do.
Not Everyone Responds the Same Way
About 10% to 15% of people taking tirzepatide in clinical trials were “non-responders,” meaning they lost less than 5% of their body weight. This rate is similar to what’s seen with semaglutide. Roughly one-third of participants lost less than 10%. Researchers don’t fully understand yet why some people respond dramatically and others barely budge, but genetics, metabolic differences, and how well someone tolerates higher doses all play a role.
Starting weight matters too. People with more weight to lose tend to see larger absolute losses. Your metabolic health, whether you have type 2 diabetes, what other medications you take, and how much your eating habits shift on the drug all influence outcomes.
Where the Weight Comes From
One of the more notable findings from the SURMOUNT-1 trial involved body composition. A substudy using body scanning found that participants on tirzepatide reduced their total body fat mass by about 34%, compared to 8% in the placebo group. That’s a significant difference, and it means a large share of the weight lost is actual fat rather than muscle or water.
Waist circumference dropped substantially at every dose. At 15 mg, the average reduction was roughly 7.3 to 7.8 inches over 72 weeks. Waist circumference is a proxy for visceral fat, the kind that wraps around organs and drives metabolic disease, so these reductions carry health significance beyond what the scale shows.
Mounjaro vs. Zepbound: Same Drug, Different Label
If you’ve seen Zepbound mentioned alongside Mounjaro, it’s worth knowing they contain the exact same active ingredient. Eli Lilly markets tirzepatide under two brand names: Mounjaro is FDA-approved for type 2 diabetes, and Zepbound is approved specifically for chronic weight management (and obstructive sleep apnea). The dual branding exists largely for insurance and prescribing purposes. The weight loss data from clinical trials applies equally to both.
What Happens If You Stop
This is the part most people don’t want to hear. A systematic review published in The Lancet’s eClinicalMedicine found that at one year after stopping GLP-1 based medications, people regained about 60% of the weight they had lost during treatment. Beyond a year, regain was estimated to plateau at roughly 75% of the lost weight. That doesn’t mean the drug “didn’t work.” It means obesity is a chronic condition, and the medication is managing it rather than curing it. Most people who achieve significant results will need to stay on the medication long-term to maintain them, similar to how blood pressure medication keeps blood pressure down only as long as you take it.
Some weight regain likely reflects the return of appetite signals that the drug was suppressing. Without tirzepatide activating those hormone pathways, hunger and food reward signals gradually normalize, and calorie intake tends to creep back up.
Realistic Expectations
If you respond well to Mounjaro and reach the higher doses, losing 15% to 20% of your starting weight over the first year is a realistic target based on trial data. For a 230-pound person, that’s 34 to 46 pounds. Some people exceed these averages, and some fall short. The first month will likely feel underwhelming, the middle months will show the most visible changes, and results typically level off after about a year.
The drug works primarily by reducing appetite and changing how your body processes energy, but it works best alongside the basics: regular physical activity and reasonable food choices. Clinical trial participants all received lifestyle counseling, and the results reflect that combination. Tirzepatide does the heavy lifting on hunger, but building sustainable habits helps protect your results, especially if you ever need to reduce your dose or come off the medication.